Cancer

Better Together: The Agency Built For This Moment Celebrates Two Years

The communications agency marks its second anniversary by addressing challenges in generative AI and supporting organizations in a changing world…

11 months ago

For A Bright Future Foundation Announces Four Single Parent Household & Families Scholarship Awardees

The Foundation recognizes Kana DeCoste, Liam Fernandes, Mariyah Newman, and Nathalia Granger who are ardently pursuing degrees in the areas of…

11 months ago

America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search

The Regeneron Science Talent Search Celebrates and Rewards Today's Most Talented Young Minds Driving Innovation and Progress through Scientific Exploration…

11 months ago

mPATH® Health is Selected as Finalist for HLTH Foundation’s Case Study Competition

Winston-Salem based digital health company is chosen as a top-10 finalist for competitive techquity program to be held at the…

11 months ago

Next-Generation Sequencing Services Market Poised for Remarkable Growth: Projected to Increase from $7 Billion in 2024 to $15 Billion by 2031: – Market Research Intellect

The Next-Generation Sequencing (NGS) Services Market is driven by several key factors, including significant advancements in sequencing technologies that enhance…

11 months ago

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions

OCALA, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that…

11 months ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

- REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC)…

11 months ago

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor…

11 months ago

ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome

Exploring the combination with azacitidineStudy led by Medical College of Wisconsin MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE)…

11 months ago

Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

Data corroborate previously reported preclinical data demonstrating certepetide’s ability to enhance the effectiveness of immunotherapy Preliminary results to be presented…

11 months ago